Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function

E Brennan, P Kantharidis, ME Cooper… - Nature Reviews …, 2021 - nature.com
Obesity, diabetes mellitus, hypertension and cardiovascular disease are risk factors for
chronic kidney disease (CKD) and kidney failure. Chronic, low-grade inflammation is …

Oxidative stress and inflammation in renal and cardiovascular complications of diabetes

A Charlton, J Garzarella, KAM Jandeleit-Dahm, JC Jha - Biology, 2020 - mdpi.com
Simple Summary The progressive nature of type 2 diabetes mellitus (T2DM) leads to micro-
and macro-vascular complications, including renal and cardiovascular disease. These …

Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis

A Sharma, JSY Choi, N Stefanovic, A Al-Sharea… - Diabetes, 2021 - Am Diabetes Assoc
Low-grade persistent inflammation is a feature of diabetes-driven vascular complications, in
particular activation of the Nod-like receptor family pyrin domain containing 3 (NLRP3) …

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

G Fredman, CN Serhan - Nature Reviews Cardiology, 2024 - nature.com
Timely resolution of the acute inflammatory response (or inflammation resolution) is an
active, highly coordinated process that is essential to optimal health. Inflammation resolution …

Lipoxin mimetics and the resolution of inflammation

C Godson, P Guiry, E Brennan - Annual Review of …, 2023 - annualreviews.org
Inflammation and its timely resolution are critical to ensure effective host defense and
appropriate tissue repair after injury and or infection. Chronic, unresolved inflammation …

How important are fatty acids in human health and can they be used in treating diseases?

LMT Dicks - Gut Microbes, 2024 - Taylor & Francis
Most of the short-chain fatty acids (SCFAs) are produced by Bifidobacterium, Lactobacillus,
Lachnospiraceae, Blautia, Coprococcus, Roseburia, Facealibacterium and Oscillospira …

Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35

CX Qin, LV Norling, EA Vecchio… - British Journal of …, 2022 - Wiley Online Library
We discuss the fascinating pharmacology of formylpeptide receptor 2 (FPR2; often referred
to as FPR2/ALX since it binds lipoxin A4). Initially identified as a low‐affinity 'relative'of …

Safety and preliminary efficacy of a novel host-modulatory therapy for reducing gingival inflammation

H Hasturk, F Schulte, M Martins, H Sherzai… - Frontiers in …, 2021 - frontiersin.org
Background Periodontal disease is among the sixth most common inflammatory diseases
worldwide with high risk to promote complications from other inflammatory diseases …

[HTML][HTML] Therapeutic potential of pro-resolving mediators in diabetic kidney disease

T Vartak, C Godson, E Brennan - Advanced drug delivery reviews, 2021 - Elsevier
Renal microvascular disease associated with diabetes [Diabetic kidney disease-DKD] is the
leading cause of chronic kidney disease. In DKD, glomerular basement membrane …

Formyl peptide receptor type 2 agonists to kick‐start resolution pharmacology

M Perretti, C Godson - British Journal of Pharmacology, 2020 - Wiley Online Library
One way to develop innovative approaches for the treatment of chronic diseases is to exploit
the biology of the resolution of inflammation. With this terminology, we identify the integrated …